Furthermore in the pasireotide group, pre-to-post-HCT changes were noted in markers previously associated with transplant outcomes including GVHD (with increases in CRP [46, 47], SAA [48], IL7 [49], TSLP [50], PlGF [51], IL6 [42], IL27 [52], TNFR1 [53], IL1RL/ST2 [54], MMP3 [55], TNFRII [56] and decreases in bFGF [57], IL12/p70 [41], IL6Ra [58], and Paraoxonase [48]), non-relapse mortality (D-Dimer [59]) and OS (Il1RL/ST2) [60]. The gene discussed is IL6; the disease is graft versus host disease.